DRG Epidemiology's coverage of colorectal cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of colorectal cancer for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the world.
DRG Epidemiology's colorectal cancer forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with colorectal cancer per year?
- In developing countries, what impact will economic growth and development have on the number of people diagnosed with colorectal cancer per year?
- How will improvements in survival change the number of people living with a diagnosis of colorectal cancer?
- How will decreasing recurrence risk change the number of first-line drug-treatment opportunities for colorectal cancer?
- Of all people diagnosed with colorectal cancer, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of colorectal cancer over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following colorectal cancer subpopulations:
- Stage II colon cancer.
- Stage II rectal cancer.
- Stage III colon cancer.
- Stage III rectal cancer.
- Stage IV colorectal cancer wild-type BRAF and RAS, first-line (left-sided).
- Stage IV colorectal cancer wild-type BRAF and RAS, first-line (right-sided).
- Stage IV colorectal cancer mutant RAS, first-line.
- Stage IV colorectal cancer mutant BRAF, first-line.
- Stage IV colorectal cancer wild-type BRAF and RAS,second-line (left-sided).
- Stage IV colorectal cancer wild-type BRAF and RAS,second-line (right-sided).
- Stage IV colorectal cancer mutant RAS, second-line.
- Stage IV colorectal cancer mutant BRAF, second-line.
- Stage IV colorectal cancer wild-type BRAF and RAS, third-line (left-sided).
- Stage IV colorectal cancer wild-type BRAF and RAS, third-line (right-sided).
- Stage IV colorectal cancer mutant RAS, third-line.
- Stage IV colorectal cancer mutant BRAF, third-line.
- … and many more (details available on request).
Note: coverage may vary by country.
- Mature Markets
- Key Findings
- Incidence of Colorectal Cancer per 100,000 per Year Among People of All Ages in 2017 and 2037
- Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Colorectal Cancer over the Next 20 Years
- Number of Incident Cases of Colorectal Cancer Avoided over the Period 2017-2037 Across the Countries Under Study
- Analysis of the Incident Cases of Colorectal Cancer in 2017 by Stage at Diagnosis
- Epidemiology Data
- Diagnosed Incident Cases
- Stage Distribution of Colorectal Cancer
- Recurrent Incident Cases of Colorectal Cancer
- Diagnosed Prevalent Cases
- Drug-Treatable Populations and Drug-Treated Populations
- Reference Materials
- Literature Review
- Risk/Protective Factors
Author(s): Narendra Parihar; Nishant Kumar, MPH
Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.
Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.